Navigation Links
Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
Date:1/8/2014

LONDON, Jan. 8, 2014 /PRNewswire/ -- Edison's comprehensive report on Cardio3 BioSciences, Healing failing hearts, analyses its C-Cure heart regenerative product, which uses a mix of powerful cell-signalling molecules to programme autologous stem cells to develop into heart muscle. This makes C-Cure a potentially powerful novel treatment for patients with weakened, scarred hearts, usually due to previous heart attacks. C-Cure showed positive efficacy endpoints in Phase II and median heart output increased by 25% relative to baseline. The CHART-1 Phase III in chronic ischaemic heart failure is underway using C-Cathez delivery to improve cell retention 3.6 fold. Data are expected in late 2015.

Based on clinical probabilities of EU 40% and US 25%, our healthcare team identifies the base case indicative value as €77 per share. Scenario risk variants range from €42 to €225 per share.

For the full report see: www.edisoninvestmentresearch.com/research/company/cardio3-biosciences

Keywords: Cardio3 BioSciences, C-Cure, autologous stem cell therapy, ischaemic heart disease, bioscience, healthcare, Edison Investment Research.

All reports published by Edison are available to download free of charge from its website.

Overview of company: Cardio3 is developing a directed autologous stem cell therapy for chronic ischaemic heart disease. Cells are isolated from bone marrow and cultures for six to eight weeks. The product is in Phase III in the EU and on Phase III hold in the US while the FDA considers a delivery system.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:Dr John Savin MBAEdison Investment Research

+44 (0)20 3077 5735Robin DavisonEdison Investment Research

+44 (0)20 3077 5737healthcare@edisongroup.comContact details: Learn more at www.edisongroup.com and connect with Edison onLinkedin

www.linkedin.com/company/edison-investment-researchTwitter

www.twitter.com/Edison_Inv_Res YouTube

www.youtube.com/edisonitv Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

GermanyLondon +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United KingdomNew York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

USSydney +61 (0)2 9258 1162

Level 25, Aurora Place

88 Phillip Street, Sydney

NSW 2000, AustraliaWellington +64 (0)4 8948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand 


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. to Discuss Third Quarter 2013 Financial Results and Provide a Business Update
3. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
4. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
5. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
6. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
7. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
8. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
9. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer — a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... , Dec. 7, 2016  Nordion, a ... General Atomics (GA), welcome today,s award by the ... Security Administration (NNSA) of the Phase II cooperative ... with Nordion and the University of Missouri Research ... funding will support the establishment of a new, ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced today ... the company,s Board of Directors. "We are ... build our business and develop our oncolytic viruses as ... said Stephen Russell , MD, PhD, CEO of ... share our vision and passion for making a difference ...
(Date:12/7/2016)... YORK and ANN ARBOR, Mich. ... privately held biopharmaceutical company developing breakthrough immune modulatory medicines, ... trial of the Company,s lead therapeutic candidate, LYC-30937- E ... is often a debilitating skin disease that is estimated ... the United States , with approximately 1.5 ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):